What are Thrombolytic agent drugs?

Thrombolytic agent drugs are pharmacologic agents that share a common mechanism (typically targeting Fibrin; plasminogen/plasmin pathway). 0 are currently marketed, with 3 more in clinical development.

Thrombolytic agent

0 marketed 3 in Phase 3

This page covers all Thrombolytic agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Fibrin; plasminogen/plasmin pathway, Plasminogen.

Targets

Fibrin; plasminogen/plasmin pathway · Plasminogen

Phase 3 pipeline (3)

thrombolysis therapy · Leiden University Medical Center · Cardiovascular
Thrombolysis therapy dissolves blood clots by activating fibrinolytic enzymes to break down fibrin and restore blood flow in occluded vessels.
Low-dose rtPA · The George Institute · Cardiovascular
Low-dose rtPA is a thrombolytic agent that activates plasminogen to dissolve blood clots by converting it to plasmin.
Intravenous rhPro-UK · First Affiliated Hospital Xi'an Jiaotong University · Cardiovascular
Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots.